Summary

Executive Summary

Azoth Analytics has released a research report titled “Cell Therapies For Type I Diabetes (2023 Edition)” which provides a complete analysis of the pipeline of Cell Therapies For Type I Diabetes, Target Market Opportunity by country and epidemiology of the Disease.

The research report covers a detailed analysis of the 15 countries (United States, Canada, Brazil, Germany, United Kingdom, Italy, France, Spain, Russia, Sweden, Poland, China, Japan, Australia, Saudi Arabia and India). Additionally, the research report presents data including Target Market opportunity, Complete pipeline analysis and the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

Type 1 diabetes is a persistent medical illness marked by a lack of treatment, and existing therapeutic interventions, such as insulin therapy, consist of inherent limits. There exists a notable and unresolved medical necessity for the development of medicines that are both more efficacious and possess prolonged durations of action.

The number of clinical studies pertaining to cell-based therapy for type 1 diabetes is steadily increasing. The attainment of positive trial outcomes has the potential to stimulate market expansion and facilitate the widespread acceptance and utilization of a drug. Individuals diagnosed with type 1 diabetes, are actively engaged in the pursuit of alternative therapeutic approaches that hold promise for either a prospective cure or sustained improvement of their medical condition.

The discipline of cell therapy for diabetes has garnered substantial investment and funding from various governmental and private entities, hence facilitating research and development endeavors. Regulatory bodies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have demonstrated an augmented inclination to collaborate with cell therapy researchers, thereby expediting the progression and authorization procedures.

The demand for a cure for Type 1 diabetes is robust and steadily increasing among individuals diagnosed with the condition. The everyday maintenance of this chronic disease can impose significant physical and mental burdens. Cell therapy presents a promising prospect for a sustainable resolution, and individuals afflicted with medical conditions are enthusiastic about investigating novel therapeutic alternatives that may yield a remedy.



Scope of the Report

• Pipeline drug profiles of Cell Therapies For Type I Diabetes

• Assessment of Disease Background, Epidemiology and Treatment Algorithm

• Target Market opportunity of Cell Therapies For Type I Diabetes by country (in USD Million).

• The key insights of the companies in the market have been presented through the framework of SWOT Analysis.

• Unmet Needs

• Profiles of Drugs and products in Pipeline

• Impact of Upcoming Therapies

• The report analyses the Epidemiology of Cell Therapies For Type I Diabetes by country.

• Major opportunities, trends, drivers and challenges.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novo Nordisk, Sanofi, Vertex Pharmaceuticals, Sernova, Throne Biotechnologies, Kadimastem, CellTrans Inc., Sigilon Therapeutics, Beta-02, and CRISPR Therapeutics AG.

ページTOPに戻る

Table of Contents

1. Introduction

1.1 Market Scope and Product Outlook

1.2 Executive Summary

2. Type 1 Diabetes Mellitus Background

2.1 Type 1 Diabetes Fact Sheet

2.2 Epidemiology

2.3 Causes and Risk Factors

2.4 Clinical Manifestations of Type I Diabetes

2.5 Diagnosis

2.6 Number of individuals with diabetes in each IDF Region, by age (2022)

2.7 Treatment Algorithm

2.8 Comparative Analysis of Cell Therapies vs Other Therapies for T1D

2.9 Approved Treatment: Landitra Overview

2.10 Number of individuals with diabetes in by top 20 countries, by age (2022)



3. Therapeutics in Pipeline

3.1 Emerging Cell Therapies in Pipeline

3.2 Emerging cell therapies in preclinical stages

3.3 Cell Therapies for Type I Diabetes Comparative Review



4. Pipeline Analysis, Assessment By Drug

4.1 VC01-103 – ViaCyte

4.1.1 Study Description

4.1.2 Endpoints



4.2 Stem Cell Educator (SCE) – Throne Biotechnologies Inc.

4.2.1 Study description

4.2.2 Endpoints



4.3 VC02-101 – ViaCyte

4.3.1 Study description

4.3.2 Endpoints



4.4 Autologous immunoregulatory dendritic cells (iDC) – DiaVacs, Inc.

4.4.1 Study Description

4.4.2 Endpoints



4.5 AVT001 – Avotres Inc.

4.5.1 Study Description

4.5.2 Endpoints



4.6 Human menstrual blood-derived MenSCs – S-Evans Biosciences Co., Ltd.

4.6.1 Study Description

4.6.2 Endpoints



4.7 PROCHYMAL® – Mesoblast, Inc.

4.7.1 Study Description

4.7.2 Endpoints



4.8 ProTrans – NextCell Pharma Ab

4.8.1 Study Description

4.8.2 Endpoints



4.9 VCTX211 – CRISPR Therapeutics AG

4.9.1 Study Description

4.9.2 Endpoints



4.10 Beta-Air – Beta-O2 Technologies

4.10.1 Study Description

4.10.2 Endpoints



4.11 VX-880 – Vertex Pharmaceuticals

4.11.1 Study Description

4.11.2 Endpoints



5. Type 1 Diabetes Landscape: Country Analysis

5.1 United States of America

5.1.1 Incidence of Type 1 Diabetes

5.1.2 Prevalence of Type 1 Diabetes

5.1.3 Target Market Opportunity, 2023-2030

5.2 Canada

5.2.1 Incidence of Type 1 Diabetes

5.2.2 Prevalence of Type 1 Diabetes

5.2.3 Target Market Opportunity, 2023-2030

5.3 Brazil

5.3.1 Incidence of Type 1 Diabetes

5.3.2 Prevalence of Type 1 Diabetes

5.3.3 Target Market Opportunity, 2023-2030

5.4 United Kingdom

5.4.1 Incidence of Type 1 Diabetes

5.4.2 Prevalence of Type 1 Diabetes

5.4.3 Target Market Opportunity, 2023-2030

5.5 Germany

5.5.1 Incidence of Type 1 Diabetes

5.5.2 Prevalence of Type 1 Diabetes

5.5.3 Target Market Opportunity, 2023-2030

5.6 France

5.6.1 Incidence of Type 1 Diabetes

5.6.2 Prevalence of Type 1 Diabetes

5.6.3 Target Market Opportunity, 2023-2030

5.7 Italy

5.7.1 Incidence of Type 1 Diabetes

5.7.2 Prevalence of Type 1 Diabetes

5.7.3 Target Market Opportunity, 2023-2030

5.8 Spain

5.8.1 Incidence of Type 1 Diabetes

5.8.2 Prevalence of Type 1 Diabetes

5.8.3 Target Market Opportunity, 2023-2030

5.9 Russia

5.9.1 Incidence of Type 1 Diabetes

5.9.2 Prevalence of Type 1 Diabetes

5.9.3 Target Market Opportunity, 2023-2030

5.10 Sweden

5.10.1 Incidence of Type 1 Diabetes

5.10.2 Prevalence of Type 1 Diabetes

5.10.3 Target Market Opportunity, 2023-2030

5.11 Poland

5.11.1 Incidence of Type 1 Diabetes

5.11.2 Prevalence of Type 1 Diabetes

5.11.3 Target Market Opportunity, 2023-2030

5.12 India

5.12.1 Incidence of Type 1 Diabetes

5.12.2 Prevalence of Type 1 Diabetes

5.12.3 Target Market Opportunity, 2023-2030

5.13 China

5.13.1 Incidence of Type 1 Diabetes

5.13.2 Prevalence of Type 1 Diabetes

5.13.3 Target Market Opportunity, 2023-2030

5.14 Australia

5.14.1 Incidence of Type 1 Diabetes

5.14.2 Prevalence of Type 1 Diabetes

5.14.3 Target Market Opportunity, 2023-2030

5.15 Saudi Arabia

5.15.1 Incidence of Type 1 Diabetes

5.15.2 Prevalence of Type 1 Diabetes

5.15.3 Target Market Opportunity, 2023-2030



6. Market Dynamics

6.1 Drivers

6.2 Restraints

6.3 Trends



7. Competitive Positioning

7.1 Market Position Matrix

7.2 Company profiles

7.2.1 Novo Nordisk

7.2.2 Sanofi

7.2.3 Vertex Pharmaceuticals

7.2.4 Sernova

7.2.5 Throne Biotechnologies

7.2.6 Kadimastem

7.2.7 CellTrans Inc.

7.2.8 Sigilon Therapeutics

7.2.9 Beta-O2

7.2.10 CRISPR Therapeutics AG